A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the BCL-2 mRNA, and of Docetaxel in Patients With Hormone-Refractory Prostate Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-03-0701
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase I/Ii Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination With Doxorubicin and Docetaxel in Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Low-Dose Docetaxel in Combination With Dexamethasone for Hormone-Refractory Prostate Cancer

Japanese Journal of Urology
Urology
2011English

BCL-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated With Taxane-Based Chemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2006English

Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2005English

A Phase II Study of Docetaxel in Patients With Relapsed and Refractory Ewing's Tumours

Sarcoma
Nuclear MedicineRadiologyImagingOncology
2003English

Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2011English

Phase II Trial of Cisplatin Plus Prednisone in Docetaxel-Refractory Castration-Resistant Prostate Cancer Patients

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer

Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy